Since its introduction, clinical literature is already replete with studies of calcium hydroxylapatite (CaHA). With the exception of a few articles on lipoatrophy, however, the vast majority of the studies have been conducted on women. In this article, the author reports his findings on the open-label protocol use of CaHA in male participants who were seeking a more prominent jawline. These men received injections of CaHA in the area of the posterior mandibular angle. Treatment results described herein were quite satisfactory, both to the participants and to the physician-investigator.